GSK plc’s interleukin-5 (IL-5) portfolio got boost as depemokimab, an ultra-long-acting biologic targeting IL-5, hit its endpoints in two phase III trials in severe asthma, setting up potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback